Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 7.25%, which has investors questioning if this is right time ...

Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.45. The firm has a market cap of $140.48 million, a price-to-earnings ratio of -0.76 and a beta of 1.04.

Lexicon Pharmaceuticals (LXRX) has disclosed a new risk, in the Capital Markets category. See what stocks are receiving ...

THE WOODLANDS, Texas — A Houston-area pharmaceutical company has struck a billion-dollar deal with the seller of Ozempic for a potential drug also aiming to combat obesity. Lexicon ...

Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The firm had revenue of $26.55 million for the quarter, compared to analyst estimates of ...

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms ...

Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a ...

For Investor and Media Inquiries:Lisa DeFrancesco Lexicon Pharmaceuticals, [email protected] Source: Lexicon Pharmaceuticals, Inc. The views and opinions expressed herein are the views ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...